OS Therapies Incorporated (NYSEAMERICAN:OSTX) Sees Large Growth in Short Interest

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 623,422 shares, a growth of 60.2% from the December 15th total of 389,268 shares. Approximately 2.0% of the company’s shares are sold short. Based on an average daily volume of 386,624 shares, the days-to-cover ratio is currently 1.6 days. Based on an average daily volume of 386,624 shares, the days-to-cover ratio is currently 1.6 days. Approximately 2.0% of the company’s shares are sold short.

Wall Street Analyst Weigh In

A number of research analysts have commented on OSTX shares. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. D. Boral Capital reissued a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Monday, January 5th. Finally, Lake Street Capital lowered their price objective on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Institutional Investors Weigh In On OS Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP acquired a new position in shares of OS Therapies during the third quarter worth $29,000. Mercer Global Advisors Inc. ADV purchased a new stake in OS Therapies during the 3rd quarter worth about $40,000. Millennium Management LLC acquired a new position in shares of OS Therapies during the 3rd quarter worth about $183,000. Virtu Financial LLC boosted its position in shares of OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after acquiring an additional 54,269 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of OS Therapies in the 3rd quarter valued at about $169,000.

OS Therapies Stock Performance

Shares of OSTX opened at $1.46 on Friday. The stock has a market capitalization of $51.41 million, a PE ratio of -1.78 and a beta of -3.79. OS Therapies has a 1 year low of $1.12 and a 1 year high of $4.54. The company’s 50-day simple moving average is $1.67 and its 200-day simple moving average is $1.86.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. On average, sell-side analysts predict that OS Therapies will post -0.64 earnings per share for the current year.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.